Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2025-01-21 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the FDA approval of a new drug (Datroway) for HR-positive, HER2-negative breast cancer, including clinical trial results, drug description, and company statements. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a significant corporate event (drug approval) but does not fit into categories like M&A, capital update, or governance. The Form 6-K is a standard SEC filing for foreign issuers to report material information and is classified under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories. The document length is substantial and contains detailed information, not just an announcement of a report, so it is not a Report Publication Announcement (RPA).
2025-01-21 English
Dato-DXd approved in US for HR+ breast cancer
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 8553T' and contains standard regulatory boilerplate language at the end, including references to 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content is a press release announcing the US FDA approval of a new drug (Datroway) for breast cancer, including clinical trial data and quotes from executives and medical professionals. This format strongly indicates a regulatory news service announcement, which falls under the general category for such disclosures. Since it is not a full annual report (10-K), a quarterly report (IR), a proxy statement (DEF 14A), or a specific management discussion (MDA), the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement distributed via the RNS system.
2025-01-20 English
CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the FDA approval of Calquence combination therapy for mantle cell lymphoma, including clinical trial results, regulatory review details, and company statements. The document is not an annual or quarterly financial report, nor is it a transcript, proxy, or governance document. It is a regulatory filing providing material information about a significant corporate event (drug approval) but does not contain financial statements or earnings data. The length (over 12,000 characters) and detailed content confirm it is a substantive regulatory announcement rather than a brief notice or certification. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-17 English
Calquence combination approved in US for 1L MCL
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 7487T' and is dated 17 January 2025. It announces a significant regulatory event: the US FDA approval of AstraZeneca's drug Calquence for mantle cell lymphoma, citing Phase III trial results. This format—a brief announcement of a material event, often referencing regulatory bodies (FDA) and clinical data, distributed via the RNS system (London Stock Exchange's news service)—is characteristic of a general regulatory announcement or press release that doesn't fit a specific financial report category like 10-K or ER. Since it is a formal, material announcement distributed through the RNS system and doesn't fit ER (Earnings Release), IR (Interim Report), or LTR (Legal Proceedings Report), the most appropriate general category for such a regulatory news service filing is RNS (Regulatory Filings). The document length (13,030 chars) is substantial enough that it is the primary document, not just a short RPA.
2025-01-17 English
TOTAL VOTING RIGHTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of December 31, 2024, including the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The document is short (3160 characters) and primarily provides an update on voting rights, not a full report or detailed financial data. It is not an annual or interim report, nor an earnings release or management discussion. It is a regulatory announcement about voting rights, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a general compliance disclosure.
2025-01-02 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official notification released via RNS (Regulatory News Service), indicated by the 'RNS Number' and the closing statement referencing RNS as the Primary Information Provider. The content explicitly states it is a notification made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, detailing the total number of voting rights and issued share capital as of a specific date (31 December 2024). This type of regulatory disclosure regarding voting rights and capital structure is a specific regulatory announcement. While it relates to capital, it is not a financing activity (CAP) or a share repurchase (POS), but rather a mandatory disclosure of the current voting rights denominator. This fits best under the general 'Regulatory Filings' (RNS) category, as it is a standard, periodic regulatory update that doesn't fit the more specific categories like DVA (which is for *results* of a vote) or SHA (which is for *changes* like splits/issues). Given the source (RNS) and the nature of the disclosure (voting rights calculation basis), RNS is the most appropriate classification.
2025-01-02 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.